Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu 610041, China.
Division of Infectious Diseases, State Key Laboratory of Biotherapy, Sichuan University, Chengdu 610041, China.
Biomolecules. 2023 Jul 28;13(8):1184. doi: 10.3390/biom13081184.
Liver X receptor α (LXRα), a member of the nuclear receptor superfamily, is identified as a protein activated by ligands that interacts with the promoters of specific genes. It regulates cholesterol, bile acid, and lipid metabolism in normal physiological processes, and it participates in the development of some related diseases. However, many studies have demonstrated that LXRα is also involved in regulating numerous human malignancies. Aberrant LXRα expression is emerging as a fundamental and pivotal factor in cancer cell proliferation, invasion, apoptosis, and metastasis. Herein, we outline the expression levels of LXRα between tumor tissues and normal tissues via the Oncomine and Tumor Immune Estimation Resource (TIMER) 2.0 databases; summarize emerging insights into the roles of LXRα in the development, progression, and treatment of different human cancers and their diversified mechanisms; and highlight that LXRα can be a biomarker and therapeutic target in diverse cancers.
肝 X 受体α(LXRα)是核受体超家族的成员之一,被鉴定为一种由配体激活的蛋白,与特定基因的启动子相互作用。它在正常生理过程中调节胆固醇、胆汁酸和脂质代谢,参与一些相关疾病的发生。然而,许多研究表明,LXRα也参与调节许多人类恶性肿瘤。异常的 LXRα表达正在成为癌细胞增殖、侵袭、凋亡和转移的基本和关键因素。在这里,我们通过 Oncomine 和 Tumor Immune Estimation Resource(TIMER)2.0 数据库概述了 LXRα在肿瘤组织和正常组织之间的表达水平;总结了 LXRα在不同人类癌症的发生、发展和治疗中的作用的新见解及其多样化的机制;并强调 LXRα可以作为不同癌症的生物标志物和治疗靶点。